talimogene laherparepvec + pembrolizumab

This drug is a combination therapy consisting of **talimogene laherparepvec (T-VEC)**, an *oncolytic herpes simplex virus type-1 immunotherapy* engineered to selectively replicate within tumors and express granulocyte-macrophage colony-stimulating factor (GM-CSF), and **pembrolizumab**, a *monoclonal antibody checkpoint inhibitor* targeting programmed cell death protein 1 (PD-1)[1][5][6][7]. T-VEC promotes local tumor cell lysis and stimulates an anti-tumor immune response, while pembrolizumab blocks the inhibitory PD-1 receptor on T cells, enhancing immune-mediated tumor elimination[5][6][7]. This combination has been investigated in clinical trials for advanced melanoma, head and neck squamous cell carcinoma, and sarcomas, aiming to synergistically augment anti-tumor immunity beyond either agent alone[1][2][3][4][5][6].

Brand names

ImlygicKeytruda

Other names

talimogene laherparepvec + pembrolizumabT-VEC + pembrolizumab